OBJECTIVE: The goal of this study was to test the ability of an injectable self-assembling peptide (KLD) hydrogel with or without chondrogenic factors (CF) and allogeneic bone marrow stromal cells (BMSCs) to stimulate cartilage regeneration in a full-thickness, critically-sized, rabbit cartilage defect model in vivo. We used CF treatments to test the hypotheses that CF would stimulate chondrogenesis and matrix production by cells migrating into acellular KLD (KLD+CF) or by BMSCs delivered in KLD (KLD+CF+BMSCs). DESIGN: Three groups were tested against contralateral untreated controls: KLD, KLD+CF, and KLD+CF+BMSCs, n=6-7. Transforming growth factor-β1 (TGF-β1), dexamethasone, and insulin-like growth factor-1 (IGF-1) were used as CF pre-mixed with KLD and BMSCs before injection. Evaluations included gross, histological, immunohistochemical and radiographic analyses. RESULTS: KLD without CF or BMSCs showed the greatest repair after 12 weeks with significantly higher Safranin-O, collagen II immunostaining, and cumulative histology scores than untreated contralateral controls. KLD+CF resulted in significantly higher aggrecan immunostaining than untreated contralateral controls. Including allogeneic BMSCs+CF markedly reduced the quality of repair and increased osteophyte formation compared to KLD-alone. CONCLUSIONS: These data show that KLD can fill full-thickness osteochondral defects in situ and improve cartilage repair as shown by Safranin-O, collagen II immunostaining, and cumulative histology. In this small animal model, the full-thickness critically-sized defect provided access to the marrow, similar in concept to abrasion arthroplasty or spongialization in large animal models, and suggests that combining KLD with these techniques may improve current practice.
OBJECTIVE: The goal of this study was to test the ability of an injectable self-assembling peptide (KLD) hydrogel with or without chondrogenic factors (CF) and allogeneic bone marrow stromal cells (BMSCs) to stimulate cartilage regeneration in a full-thickness, critically-sized, rabbit cartilage defect model in vivo. We used CF treatments to test the hypotheses that CF would stimulate chondrogenesis and matrix production by cells migrating into acellular KLD (KLD+CF) or by BMSCs delivered in KLD (KLD+CF+BMSCs). DESIGN: Three groups were tested against contralateral untreated controls: KLD, KLD+CF, and KLD+CF+BMSCs, n=6-7. Transforming growth factor-β1 (TGF-β1), dexamethasone, and insulin-like growth factor-1 (IGF-1) were used as CF pre-mixed with KLD and BMSCs before injection. Evaluations included gross, histological, immunohistochemical and radiographic analyses. RESULTS:KLD without CF or BMSCs showed the greatest repair after 12 weeks with significantly higher Safranin-O, collagen II immunostaining, and cumulative histology scores than untreated contralateral controls. KLD+CF resulted in significantly higher aggrecan immunostaining than untreated contralateral controls. Including allogeneic BMSCs+CF markedly reduced the quality of repair and increased osteophyte formation compared to KLD-alone. CONCLUSIONS: These data show that KLD can fill full-thickness osteochondral defects in situ and improve cartilage repair as shown by Safranin-O, collagen II immunostaining, and cumulative histology. In this small animal model, the full-thickness critically-sized defect provided access to the marrow, similar in concept to abrasion arthroplasty or spongialization in large animal models, and suggests that combining KLD with these techniques may improve current practice.
Authors: John D Kisiday; Paul W Kopesky; Christopher H Evans; Alan J Grodzinsky; C Wayne McIlwraith; David D Frisbie Journal: J Orthop Res Date: 2008-03 Impact factor: 3.494
Authors: Paul W Kopesky; Eric J Vanderploeg; John D Kisiday; David D Frisbie; John D Sandy; Alan J Grodzinsky Journal: Tissue Eng Part A Date: 2010-09-22 Impact factor: 3.845
Authors: Janna K Mouw; John T Connelly; Christopher G Wilson; Kristin E Michael; Marc E Levenston Journal: Stem Cells Date: 2006-11-22 Impact factor: 6.277
Authors: D D Frisbie; S M Bowman; H A Colhoun; E F DiCarlo; C E Kawcak; C W McIlwraith Journal: Osteoarthritis Cartilage Date: 2007-11-26 Impact factor: 6.576
Authors: Philip D Tatman; Ethan G Muhonen; Sean T Wickers; Albert O Gee; Eung-Sam Kim; Deok-Ho Kim Journal: Biomater Sci Date: 2016-02-15 Impact factor: 6.843
Authors: Paul H Liebesny; Keri Mroszczyk; Hannah Zlotnick; Han-Hwa Hung; Eliot Frank; Bodo Kurz; Gustavo Zanotto; David Frisbie; Alan J Grodzinsky Journal: Tissue Eng Part A Date: 2019-09-03 Impact factor: 3.845
Authors: Paul W Kopesky; Sangwon Byun; Eric J Vanderploeg; John D Kisiday; David D Frisbie; Alan J Grodzinsky Journal: J Biomed Mater Res A Date: 2013-06-04 Impact factor: 4.396
Authors: Kyobum Kim; Johnny Lam; Steven Lu; Patrick P Spicer; Aline Lueckgen; Yasuhiko Tabata; Mark E Wong; John A Jansen; Antonios G Mikos; F Kurtis Kasper Journal: J Control Release Date: 2013-03-28 Impact factor: 9.776
Authors: Emily M Florine; Rachel E Miller; Paul H Liebesny; Keri A Mroszczyk; Richard T Lee; Parth Patwari; Alan J Grodzinsky Journal: Tissue Eng Part A Date: 2014-10-23 Impact factor: 3.845
Authors: Rachel E Miller; Alan J Grodzinsky; Myra F Barrett; Han-Hwa Hung; Eliot H Frank; Natasha M Werpy; C Wayne McIlwraith; David D Frisbie Journal: J Bone Joint Surg Am Date: 2014-10-01 Impact factor: 5.284